Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Endo International plc is a specialty pharmaceutical company focused on developing, manufacturing, marketing, and distributing high-value branded and generic pharmaceutical products. The company aims to improve patients' lives by providing quality medicines and addressing unmet medical needs, primarily in the United States. Following a financial restructuring, Endo emerged from Chapter 11 in April 2023 as a private company owned by its former first-lien lenders.
Serves as the official registered office and global corporate headquarters, responsible for corporate governance, strategic oversight, and international financial management.
Modern office facility located in a prominent business district, designed to support global administrative and strategic operations.
The corporate culture is expected to be focused on pharmaceutical innovation, regulatory compliance, ethical practices, and driving growth. Post-restructuring, there is likely a strong emphasis on efficiency, financial discipline, and rebuilding value.
The Dublin headquarters is strategically important for Endo's international corporate structure, governance, and global financial operations. It signifies its status as a global pharmaceutical entity.
While Endo International plc is headquartered in Dublin, Ireland, its primary commercial and operational focus is concentrated in the United States. Global functions supported include corporate strategy and governance from Ireland, with extensive U.S.-based operations covering research & development, manufacturing of specialty branded and generic pharmaceuticals, and comprehensive commercialization activities. The company also has manufacturing facilities and may engage in international partnerships or licensing for specific products beyond the U.S.
First Floor, Minerva House, Simmonscourt Road, Ballsbridge
Dublin
D04 E5T6
Ireland
Address: 1400 Atwater Dr, Malvern, PA 19355, USA
Manages and executes the company's strategy for the U.S. pharmaceutical market, overseeing the development, manufacturing, marketing, and sales of branded and generic products in the region.
Address: 6 Ram Ridge Road, Chestnut Ridge, NY 10977, USA
Supports Endo's generics business segment (Par Pharmaceutical) with manufacturing capabilities and product development for the U.S. market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Endo Pharmaceuticals' leadership includes:
Endo Pharmaceuticals has been backed by several prominent investors over the years, including:
Following its emergence from Chapter 11 restructuring in April 2023, Endo International plc confirmed its key leadership team. The past 12 months have focused on operational stability and growth for the new private entity, with the existing leadership largely transitioning with the restructured company. No major high-profile external hires or departures from the core executive team have been publicly announced in this period.
Discover the tools Endo Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Endo International plc, like many corporations, uses standardized email formats. The most common formats are typically a combination of the employee's first name, last name, or initials with the company domain '@endo.com'.
[first_initial][last_name]@endo.com (e.g., jsmith@endo.com) and [first_name].[last_name]@endo.com (e.g., john.smith@endo.com) are common structures.
Format
bcoleman@endo.com or blaise.coleman@endo.com
Example
80%
Success rate
PR Newswire / Endo International plc • April 25, 2023
Endo International plc announced its emergence from Chapter 11 proceedings, having completed its financial restructuring. The company is now a private entity, owned by its former first-lien debtholders, and is focused on its mission of providing essential medicines to patients....more
Endo International plc Press Release • October 3, 2023
Endo International plc announced that its operating company, Endo Pharmaceuticals Inc., received U.S. Food and Drug Administration (FDA) approval for an additional 13.5 mg dosage strength of XTAMPZA ER (oxycodone extended-release capsules) with separately co-packaged naloxone hydrochloride nasal spray and has commenced shipment to wholesalers....more
Reuters • March 17, 2023
A U.S. bankruptcy judge approved Endo International's bankruptcy restructuring plan, which included a settlement of widespread lawsuits alleging the company fueled the U.S. opioid epidemic. The plan outlined payments to an opioid settlement trust and a transfer of company ownership to lenders....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Endo Pharmaceuticals, are just a search away.